大唐药业(836433) - 2023 Q4 - 年度业绩预告

Financial Performance - The net profit attributable to shareholders for 2023 is expected to be 7.644 million yuan, a decrease of 48.61% compared to 14.8731 million yuan in the same period last year[3]. - The decline in net profit is primarily due to a reduction in government subsidies received, increased marketing expenses, and a decrease in investment income from bank financial products[4][5]. Expenses and Investments - The company has increased its market investment efforts to further expand sales channels, leading to higher sales expenses compared to the previous year[4]. - The company has also seen an increase in inventory impairment provisions and depreciation expenses due to the ongoing construction of the health technology industrial park project[5]. Financial Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, urging investors to be cautious about investment risks[6].